HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy

Journal of Immunotherapy

Volumn 33, Issue 4, 2010, Pages 402-413

  Fauquembergue, Emilie ^a   Toutirais, Olivier ^a   Tougeron, David ^a,c   Drouet, Aurelie ^a   Gallo, Matthieu Le ^b   Desille, Mireille ^a   Cabillic, Florian ^b,d   De La Pintière, Cécile Thomas ^d   Iero, Manuela ^e   Rivoltini, Licia ^e   Baert Desurmont, Stéphanie ^c   Leprince, Jérôme ^f   Vaudry, Hubert ^f   Sesboué, Richard ^a,c   Frébourg, Thierry ^a,c   Latouche, Jean Baptiste ^a,c   Catros, Véronique ^a,d  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITÉ DE ROUEN   (France)

Author keywords

Artificial antigen presenting cells; Cap1 peptide; Carcinoembryonic antigen; Cytotoxic t cells; Retroviral transduction; T cell based immunotherapy

Indexed keywords

AUTOANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC CAP1 ANTIGEN; HLA A ANTIGEN; UNCLASSIFIED DRUG; CAP1 6D; CAP1-6D; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; OLIGOPEPTIDE;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL CLONING; CELL STIMULATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTIGEN PRESENTATION; CARCINOMA; CELL STRAIN 3T3; CELL STRAIN HT29; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR CLONING; PATHOLOGY;

3T3 CELLS; ANIMALS; ANTIGEN PRESENTATION; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CLONING, MOLECULAR; HLA-A ANTIGENS; HT29 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; OLIGOPEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 85047699922     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181d366da     Document Type: Article

References (41)

1. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
2. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666.
3. Saeterdal I, Bjorheim J, Lislerud K, et al. Frameshiftmutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A. 2001;98:13255-13260.
4. Koch M, Beckhove P, Op den Winkel J, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg. 2006;244:986-992; discussion 992-983.
5. Van der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002;188:51-64.
6. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67-81.
7. Blumenthal RD, Leon E, Hansen HJ, et al. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 2007;7:2.
8. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995;87:982-990.
9. Zaremba S, Barzaga E, Zhu M, et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997;57:4570-4577.
10. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol. 2002;20:2197-2207.
11. Mosolits S, Nilsson B, Mellstedt H. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev Vaccines. 2005;4:329-350.
12. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001;98:8809-8814.
13. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008;112:610-618.
14. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol. 2000;18:405-409.
15. Papanicolaou GA, Latouche JB, Tan C, et al. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood. 2003;102:2498-2505.
16. Dupont J, Latouche JB, Ma C, et al. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitopespecific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 2005;65:5417-5427.
17. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999;59:5800-5807.
18. Zhu M, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 2001;61:3725-3734.
19. Ory DS, Neugeboren BA, Mulligan RC. A stable humanderived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A. 1996;93:11400-11406.
20. Iero M, Squarcina P, Romero P, et al. Low TCR avidity and lack of tumor cell recognition in CD8 (+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother. 2007;56:1979-1991.
21. Labarriere N, Diez E, Pandolfino MC, et al. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol. 1997;158:1238-1245.
22. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A. 1995;92:6733-6737.
23. Gallardo HF, Tan C, Sadelain M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther. 1997;4:1115-1119.
24. Riviere I, Sadelain M. Methods for the construction of retroviral vectors and the generation of high-titer producers. In: Robbins PD, ed. Gene Therapy Protocols. Totowa, NJ: Humana Press; 1997:59-78.
25. Young JW, Steinman RM. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J Exp Med. 1990;171:1315-1332.
26. Gervois N, Guilloux Y, Diez E, et al. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med. 1996;183:2403-2407.
27. Shao L, Allez M, Park MS, et al. Immunomodulatory roles of the carcinoembryonic antigen family of glycoproteins. Ann N Y Acad Sci. 2006;1072:194-209.
28. Schirle M, Keilholz W, Weber B, et al. Identification of tumorassociated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol. 2000;30:2216-2225.
29. Hou Y, Kavanagh B, Fong L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol. 2008;180:1526-1534.
30. Salazar E, Zaremba S, Arlen PM, et al. Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int J Cancer. 2000;85:829-838.
31. Mennuni C, Calvaruso F, Facciabene A, et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer. 2005;117:444-455.
32. Conforti A, Peruzzi D, Giannetti P, et al. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses. J Immunother. 2009;32:744-754.
33. Parkhurst MR, Joo J, Riley JP, et al. Characterization of genetically modified T-cell receptors that recognize the CEA: 691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res. 2009;15:169-180.
34. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998;16:364-369. (Pubitemid 28164657)
35. Matera L, Beltramo E, Martinuzzi E, et al. Effect of prolactin on carcinoembryonic antigen-specific cytotoxic T lymphocyte response induced by dendritic cells. Clin Exp Immunol. 2004;137:320-328.
36. Alters SE, Gadea JR, Sorich M, et al. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother. 1998;21:17-26.
37. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
38. Kawashima I, Hudson SJ, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998;59:1-14.
39. Miyagi T, Tatsumi T, Takehara T, et al. Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells. J Gastroenterol Hepatol. 2003;18:32-40.
40. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol. 2006;24:571-606.
41. Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity. 2005;22:275-284.